These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16900411)

  • 1. Correlation between inertial impaction and laser diffraction sizing data for aerosolized carrier-based dry powder formulations.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Pharm Res; 2006 Sep; 23(9):2200-9. PubMed ID: 16900411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.
    Martin GP; Marriott C; Zeng XM
    Pharm Res; 2007 Feb; 24(2):361-9. PubMed ID: 17177114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction.
    Martin GP; MacRitchie HB; Marriott C; Zeng XM
    Pharm Res; 2006 Sep; 23(9):2210-9. PubMed ID: 16900410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate.
    Larhrib H; Zeng XM; Martin GP; Marriott C; Pritchard J
    Int J Pharm; 1999 Nov; 191(1):1-14. PubMed ID: 10556735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate.
    Tee SK; Marriott C; Zeng XM; Martin GP
    Int J Pharm; 2000 Nov; 208(1-2):111-23. PubMed ID: 11064216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation.
    Zeng XM; Martin GP; Tee SK; Ghoush AA; Marriott C
    Int J Pharm; 1999 May; 182(2):133-44. PubMed ID: 10341303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2008 Jun; 358(1-2):75-81. PubMed ID: 18359587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
    Sethuraman VV; Hickey AJ
    AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.
    Kaialy W; Martin GP; Ticehurst MD; Royall P; Mohammad MA; Murphy J; Nokhodchi A
    AAPS J; 2011 Mar; 13(1):30-43. PubMed ID: 21057906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
    Lucas P; Anderson K; Staniforth JN
    Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.
    Chan HK; Clark A; Gonda I; Mumenthaler M; Hsu C
    Pharm Res; 1997 Apr; 14(4):431-7. PubMed ID: 9144727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.